NCI-MATCH / EAY131 Findings and Publications
Treatment arm findings and publications on special topics about the NCI-MATCH precision medicine trial appear on a rolling basis. This section of the website contains a comprehensive list of all publications associated with the trial. See the table below. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.
We update this table on an ongoing basis as new publications appear.
| Topic | Title and Citation |
|---|---|
| Arm A Final Results | Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A |
| Arm K1 Final Results | Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 |
| Arm K2 Final Results | Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 |
| Arm J Final Results | Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCIāMATCH ECOGāACRIN Trial (EAY131) Subprotocol J |
| Arm E Final Results | Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E |
| Implementation | The NCI-MATCH trial: lessons for precision oncology O'Dwyer PJ. Nature Medicine. June 2023 |
| Arm Z1B Final Results | Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B Clark AS. Clin Cancer Res. April 2023 |
| Arms S1 & S2 Final Results | Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2 Wisinski KB. JCO Precis Oncol. April 2023 |
| Arm B Final Results | Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2āActivating Mutations: Results From the National Cancer InstituteāMolecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B |
| Arms F & G Final Results | Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial |
| Arm I Final Results | Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I |
| Arm Z1F Final Results | Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F |
| Arm Z1A Final Results | Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors Cleary JM.Ā Clin Cancer Res. June 2021 |
| Arm Y Final Results | Effect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial Kalinsky KM. JAMA Oncol. December 2020 |
| Central Screening Cohort | Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Flaherty KT, J Clin Oncol. October 2020 |
| Physician Survey | Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial Chen AP, JCO Precis Oncol. October 2020 |
| Arm H Final Results | Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H Salama AKS. J Clin Oncol. August 2020 |
| Arm W Final Results | Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W Chae YK. J Clin Oncol. May 2020 |
| Arm R Final Results | Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131) Johnson DB. Clin Cancer Res. April 2020 |
| Implementation | The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design Flaherty KT. J Natl Cancer Inst. January 2020 |
| Arm Z1D Final Results | Nivolumab Is Effective in Mismatch RepairāDeficient Noncolorectal Cancers: Results From Arm Z1DāA Subprotocol of the NCI-MATCH (EAY131) Study Azad NS. J Clin Oncol. January 2020 |
| Arm Q Final Results | Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q Jhaveri KL. Ann Oncol. November 2019 |
| Immunohistochemical Assays | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial Koury JD. Clin Cancer Res. January 2018 |
| Next-Gen Sequencing Assay | Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience Lih CJ. Curr Probl Cancer. May-June 2017 |
| Defining Precision | Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH O'Sullivan Coyne G. Curr Probl Cancer. May-June 2017 |
| Next-Gen Sequencing Assay | Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial Lih CJ. J Mol Diagn. March 2017 |
| Overview | An overview of the NCI Precision Medicine trials-NCI MATCH and MPACT Do K. Chin Clin Oncol. September 2015 |
| Overview | Molecular Analysis for Therapy Choice: NCI MATCH Conley BA. Semin Oncol. June 2014 |
